会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Gamma-conopeptides
    • 伽玛肽
    • US06624288B1
    • 2003-09-23
    • US09210952
    • 1998-12-15
    • Michael FainzilberKarel S. KitsAlma L. BurlingameBaldomero M. OliveraCraig WalkerMaren WatkinsReshma ShettyLourdes J. CruzJulita ImperialClark Colledge
    • Michael FainzilberKarel S. KitsAlma L. BurlingameBaldomero M. OliveraCraig WalkerMaren WatkinsReshma ShettyLourdes J. CruzJulita ImperialClark Colledge
    • C07K500
    • C07K14/43504A61K38/00
    • This invention relates to relatively short peptides about 25-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogs to the naturally available peptides, and which include three cyclizing disulfide linkages and one or more &ggr;-carboxyglutamate residues. More specifically, the present invention is directed to &ggr;-conopeptides having the general formula I: Xaa1-Cys-Xaa2-Cys-Xaa3-Xaa4-Cys-Cys-Xaa5-Cys-Xaa6-Cys-Xaa7 (SEQ ID NO:1), as described herein; or having the general formula II: Xaa1-Cys-Xaa2-Cys-Xaa3-Xaa4-Cys-Cys-Xaa5-Xaa6-Cys-Xaa7-Cys-Xaa8 (SEQ ID NO:2), as defined herein; or having the general formula III: Xaa1-Cys-Xaa2-Cys-Xaa3-Xaa4-Xaa5-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Xaa2-Cys-Xaa7 (SEQ ID NO:3), as described herein; or having the general formula IV: Xaa1-Cys-Xaa2-Cys-Xaa3-Xaa4-Xaa5-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Xaa6-Cys-Xaa7 (SEQ ID NO:4), as described herein; or having the general formula V: Xaa1-Xaa2-Cys-Xaa3-Xaa4-Phe-Xaa5-Cys-Thr-Xaa6-Ser-Xaa7-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Gln-Thr-Tyr-Cys-Xaa8-Leu-Xaa9 (SEQ ID NO:5), as described herein. The invention further relates to specific &ggr;-conopeptides, specific pro-&ggr;-conopeptides and nucleic acids encoding the pro-&ggr;-conopeptides. The invention also includes pharmaceutically acceptable salts of the conopeptides. These conopeptides are useful as agonists of neuronal pacemaker calcium channels.
    • 本发明涉及长度约25-40个残基的相对较短的肽,其在锥形蜗牛的毒液中或天然存在的肽的类似物中天然可用量少,并且其包括三个环化二硫键和一个或多个γ- 羧基谷氨酸残基。 更具体地,本发明涉及具有通式I的X射线衍生肽:Xaa1-Cys-Xaa2-Cys-Xaa3-Xaa4-Cys-Cys-Xaa5-Cys-Xaa6-Cys-Xaa7(SEQ ID NO:1) ,如本文所述; 或具有如本文所定义的通式II:Xaa1-Cys-Xaa2-Cys-Xaa3-Xaa4-Cys-Cys-Xaa5-Xaa6-Cys-Xaa7-Cys-Xaa8(SEQ ID NO:2) 或具有通式III:Xaa1-Cys-Xaa2-Cys-Xaa3-Xaa4-Xaa5-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Xaa2-Cys-Xaa7(SEQ ID NO:3) 在这里 或具有通式IV:Xaa1-Cys-Xaa2-Cys-Xaa3-Xaa4-Xaa5-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Xaa6-Cys-Xaa7(SEQ ID NO:4) 在这里 或具有通式V:Xaa1-Xaa2-Cys-Xaa3-Xaa4-Phe-Xaa5-Cys-Thr-Xaa6-Ser-Xaa7-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Gln-Thr-Tyr -Cys-Xaa8-Leu-Xaa9(SEQ ID NO:5),如本文所述。 本发明进一步涉及具体的γ-配体肽,特异性前-γ-肽和编码前γ-多肽的核酸。 本发明还包括肽的药学上可接受的盐。 这些肽可用作神经元起搏器钙通道的激动剂。
    • 10. 发明申请
    • Method For Assembly Of Polynucleic Acid Sequences
    • US20120040870A1
    • 2012-02-16
    • US13140473
    • 2009-12-18
    • Austin CheTom KnightBarry CantonJason KellyReshma Shetty
    • Austin CheTom KnightBarry CantonJason KellyReshma Shetty
    • C12P19/34C40B50/06
    • C12N15/66C12N15/1093C12N15/64
    • The present invention provides a method for the assembly of a polynucleic acid sequence from a plurality of nucleic acid sequences in which the polynucleic acid sequence is of a formula Nn+1, in which N represents a nucleic acid sequence and where n is 1 or greater than 1 and each N may be the same or a different nucleic acid sequence, in which the method comprises: (i) providing a first nucleic acid sequence N1 which has an oligonucleotide linker sequence L13 at the 3′-end of the nucleic acid sequence; (ii) providing a second nucleic acid sequence N2 which optionally has an oligonucleotide linker sequence L23′ at the 3′-end of the nucleic acid sequence and which has an oligonucleotide linker sequence L25′ at the 5′-end of the nucleic acid sequence, wherein the 5′-end linker sequence L25′ of nucleic acid sequence N2 is complementary to the 3′-end linker sequence L13′ of nucleic acid sequence N1; (iii) optionally providing one or more additional nucleic acid sequences N, wherein nucleic acid sequence N2 has an oligonucleotide linker sequence L23′ at the 3′-end of the nucleic acid sequence, and wherein said one or more additional nucleic acid sequences N comprises a terminal additional nucleic acid sequence NZ, and wherein each additional nucleic acid sequence N has an oligonucleotide linker sequence at its 3′-end, wherein said terminal additional nucleic acid sequence NZ optionally lacks an oligonucleotide linker sequence at its 3′-end and wherein each additional nucleic acid sequence N has an oligonucleotide linker sequence at its 5′-end, wherein for the first additional nucleic acid sequence N3 the 5′-end linker sequence L35′ is complementary to the 3′-end linker sequence L23′ of nucleic acid sequence N2 and for each second and subsequent additional nucleic acid sequence N the 5′-end linker sequence is complementary to the 3′-end linker sequence of the respective preceding additional nucleic acid sequence; and (iv) ligating said nucleic acid sequences to form said polynucleic acid sequence.